enteris-biopharma-logo.png

Press Release

Enteris BioPharma Announces Acceptance
of Two Abstracts for Presentation
at ENDO 2022 Annual Conference

Boonton, NJ – April 12, 2022Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced today that two submitted abstracts were accepted for poster presentations at the 104th annual meeting of The Endocrine Society (ENDO 2022) taking place June 11-14, 2022, in Atlanta, Georgia. The abstracts highlight research into oral formulations of leuprolide developed utilizing Enteris' proprietary Peptelligence® platform, a novel formulation technology that enables oral delivery of molecules that are typically injected, including peptides and BCS class III and IV small molecules.

READ FULL PRESS RELEASE


    EnterisBioPharma is committed to protecting and respecting your privacy, and we’ll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below to say how you would like us to contact you:

    You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

    By clicking submit below, you consent to allow EnterisBioPharma to store and process the personal information submitted above to provide you the content requested.



    Meet Enteris Biopharma at ENDO 2022

    June 11-14, Atlanta, GA


    GENERAL INQUIRY

    To learn more about our technologies and CMO service offerings please fill out and submit the form.

      How did you hear about us?*

      I am interested in:

      Name*

      Company*

      Email*

      Message